Skip to search formSkip to main contentSkip to account menu

AF267B

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
AF 710 B , a Novel M 1 / σ 1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer ’ s Disease
We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and… 
2006
2006
Drug shows promise for treatment of Alzheimer's disease
2006
2006
Activation of M1 Muscarinic Receptors by AF267B Protects Hippocampal Neurons from Amyloid β Peptide Toxicity by Acting on the WNT Signalling
A loss of pre-synaptic cholinergic neurons, as observed in Alzheimer’s disease (AD), may lead to a decrease in M1 muscarinic… 
Highly Cited
2002
Highly Cited
2002
AF150(S) and AF267B
The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren’s Syndrome), AF150(S) and AF267B… 
2002
2002
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren's Syndrome), AF150(S) and AF267B… 
2001
2001
Effects of metrifonate on the hippocampal theta rhythm of freely moving intact and MS-lesioned mice
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)